Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Account Payables (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Change in Account Payables for 9 consecutive years, with -$439992.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 2845.26% year-over-year to -$439992.0, compared with a TTM value of -$185070.0 through Dec 2025, down 573.64%, and an annual FY2025 reading of $239983.0, up 258.22% over the prior year.
  • Change in Account Payables was -$439992.0 for Q4 2025 at Neuroone Medical Technologies, down from $526943.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $602635.0 in Q3 2022 and bottomed at -$439992.0 in Q4 2025.
  • Average Change in Account Payables over 5 years is $1396.8, with a median of -$18435.0 recorded in 2021.
  • Peak annual rise in Change in Account Payables hit 3746.27% in 2025, while the deepest fall reached 2845.26% in 2025.
  • Year by year, Change in Account Payables stood at $291172.0 in 2021, then crashed by 152.92% to -$154098.0 in 2022, then skyrocketed by 151.61% to $79527.0 in 2023, then tumbled by 118.78% to -$14939.0 in 2024, then tumbled by 2845.26% to -$439992.0 in 2025.
  • Business Quant data shows Change in Account Payables for NMTC at -$439992.0 in Q4 2025, $526943.0 in Q3 2025, and -$367845.0 in Q2 2025.